Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Table 9

Comparison of adverse events between our study and previous studies of intrathecal non-MSCs stem cells.

Adverse events (person-time)	Total (%)	Our study (%)	Literature review (%)
Headache	114 (8.21)	3 (2.05)	111 (8.94)	0.007
Dizziness	2 (0.14)	2 (1.37)	0 (0.00)	0.011
Fever	114 (8.21)	5 (3.42)	109 (8.78)	0.026
Nausea	20 (1.44)	2 (1.37)	18 (1.45)	1.000
Pain at puncture site	32 (2.30)	6 (4.11)	26 (2.10)	0.125
Neck pain	1 (0.07)	1 (0.68)	0 (0.00)	0.105